Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter-retrospective study.
Fiche publication
Date publication
février 2018
Journal
Journal of the American Academy of Dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LIPSKER Dan
Tous les auteurs :
Cesbron E, Bessis D, Jachiet M, Lipsker D, Cordel N, Bouaziz JD, Bagot M, Arnaud L, Barbaud A, Francès C, Chasset F,
Lien Pubmed
Mots clés
Adult, Age Distribution, Aged, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, France, Hospitals, University, Humans, Immunosuppressive Agents, adverse effects, Incidence, Lupus Erythematosus, Cutaneous, diagnosis, Male, Middle Aged, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Rate, Thalidomide, adverse effects, Thromboembolism, chemically induced
Référence
J. Am. Acad. Dermatol.. 2018 Feb 26;: